• NEBANNER

OEM Factory for Hpa Cas No.25584-83-2 - Rivaroxaban(S)-Rivaroxaban;BAY 59-7939;RivaroxabanIsomer;Rivaroxaban; – JIN DUN

OEM Factory for Hpa Cas No.25584-83-2 - Rivaroxaban(S)-Rivaroxaban;BAY 59-7939;RivaroxabanIsomer;Rivaroxaban; – JIN DUN

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

Persisting in "High high quality, Prompt Delivery, Aggressive Price", we've established long-term cooperation with clients from the two overseas and domestically and get new and old clients' superior comments for Surface Coating Technologies, Charcoal Water Filter System, Isopropylthioxanthone, The team of our company with the use of cutting-edge technologies delivers impeccable quality products supremely adored and appreciated by our customers worldwide.
OEM Factory for Hpa Cas No.25584-83-2 - Rivaroxaban(S)-Rivaroxaban;BAY 59-7939;RivaroxabanIsomer;Rivaroxaban; – JIN DUN Detail:

Used in adult patients with elective hip or knee replacement surgery to prevent venous thrombosis (VTE).

It is used to prevent or reduce the formation of thrombosis, deep vein thrombosis (DVT) and pulmonary embolism (PE) after hip or knee replacement surgery.

The recommended dose is oral rivaroxaban 10mg, once a day. Rivaroxaban 10mg can be taken with food or alone. Rivaroxaban 15mg or 20mg tablets should be taken with food.

standard: usp40
Assay: 99-102%

Exterior: White powder
Package : 25kg/drum

Take 4-(4-aminophenyl) morpholin-3-one (SM-1), (S)-N-glycidyl phthalimide (SM-2), 5-chlorothiophene-2- Formyl chloride (SM-3) is the starting material. After condensation, cyclization, aminolysis and acylation, the crude rivaroxaban is obtained, and the finished rivaroxaban is refined.
Preparation: This product is a red film-coated tablet.

Accessories:
Tablet core: microcrystalline cellulose, croscarmellose sodium, lactose monohydrate, hypromellose, sodium lauryl sulfate, magnesium stearate
Coating: polyethylene glycol, hypromellose, titanium dioxide, iron oxide red

Rivaroxaban is a highly selective, oral drug that directly inhibits factor Xa. Through highly selective and competitive inhibition of free and bound factor Xa and prothrombin activity, prolong the activated partial thromboplastin time plate (PT) and prothrombin time (aPTT) in a dose-dependent manner, which can interrupt the coagulation waterfall The endogenous and exogenous pathways inhibit the production of thrombin and thrombosis. Rivaroxaban does not inhibit thrombin (activating factor Ⅱ), nor has it proven to have an effect on platelets
The essential difference between rivaroxaban and fondaparinux/heparin is that it does not require the participation of antithrombin III and can directly antagonize free and bound factor Xa; while heparin requires antithrombin III to function, and It has no effect on factor Xa in the prothrombin complex.


Product detail pictures:

OEM Factory for Hpa Cas No.25584-83-2 - Rivaroxaban(S)-Rivaroxaban;BAY 59-7939;RivaroxabanIsomer;Rivaroxaban; – JIN DUN detail pictures


Related Product Guide:

We emphasize advancement and introduce new products into the market each year for OEM Factory for Hpa Cas No.25584-83-2 - Rivaroxaban(S)-Rivaroxaban;BAY 59-7939;RivaroxabanIsomer;Rivaroxaban; – JIN DUN , The product will supply to all over the world, such as: Greece, New Zealand, California, Our company abides by the management idea of "keep innovation, pursue excellence". On the basis of assuring the advantages of existing products, we continuously strengthen and extend product development. Our company insists on innovation to promote the sustainable development of enterprise, and make us become the domestic high-quality suppliers.
  • This enterprise in the industry is strong and competitive, advancing with the times and develop sustainable, we are very pleased to have a opportunity to cooperate!
    5 Stars By Penny from Vietnam - 2017.08.18 11:04
    This company has a lot of ready-made options to choose and also could custom new program according to our demand, which is very nice to meet our needs.
    5 Stars By Queena from Congo - 2018.06.05 13:10
    Write your message here and send it to us